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Summary
 Background Exploitation of the several types of information on patient, disease and treatment 
variables ranging from sociological to genetic ones by means of chemometric 
analysis was considered and evaluated.
 Aim Performance of modern data processing methods, namely principal component 
analysis (PCA) and artiﬁ cial neural network (ANN) analysis, is demonstrated for 
predictions of the recurrence of breast cancer in patients treated previously with 
mastectomy.
 Materials/Methods The data on 718 patients were retrospectively evaluated. 11 subject and treatment 
variables were determined for each patient. A matrix of 718×11 data points was 
subjected to PCA and ANN processing. The properly trained ANN was used to 
predict the patients with recurrence and without recurrence within a 10-year pe-
riod after mastectomy.
 Results It was found that the prognostic potency of the trained and validated ANN was 
reasonably high. Additionally, using the principal component analysis (PCA) 
method two principal components, PC1 and PC2, were extracted from the in-
put data. They accounted cumulatively for 37.5% of the variance of the data an-
alyzed. An apparent clustering of the variables and patients was observed – these 
have been interpreted in terms of their similarities and dissimilarities.
 Conclusions It has been concluded that ANN analysis offers a promising implementation to 
established methods of statistical analysis of multivariable data on cancer patients. 
On the other hand, PCA has been recommended as an alternative to classical re-
gression analysis of multivariable clinical data. By means of ANN and PCA prac-
tically useful systematic information may be extracted from large sets of data, 
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BACKGROUND
Breast cancer has become the commonest ma-
lignant disease causing the death of women in 
the European Community [1–3]. Increasing in-
cidence in all Western countries is observed. This 
includes Poland, where approximately 11 thou-
sand cases of the disease are reported annually 
[4,5]. Breast cancer still confronts us with many 
unsolved problems and open questions about op-
timal treatment, prediction of recurrence and po-
tential beneﬁ ts of supplementary treatment.
Treatment strategy in breast cancer depends on the 
stage of development. Patients in an early stage of 
the disease are treated by primary surgery and/or 
radiotherapy. When the disease becomes more ad-
vanced or metastatic treatment starts with primary 
chemotherapy and/or radiotherapy and/or hor-
monotherapy. Further decisions concerning thera-
peutic strategy depend on the prediction of possi-
ble recurrence and response to therapy. However, 
reliable prediction is extremely difﬁ cult because of 
the lack of a single prognostic parameter or iden-
tiﬁ ed combinations of them [3,6].
Several factors have been recommended to help 
in the prognosis of both overall survival and re-
currence-free interval in patients with breast tu-
mours. However, considered separately those fac-
tors usually appear disputable. The best-known 
example is the patient’s age. It has been demon-
strated eventually (in statistical terms) that age 
under 35 is an independent prognostic factor 
for an unfavourable recurrence [7–9]. On the 
other hand, age over 50 years (post-menopausal 
women) was shown in several studies to provide 
a better prognosis [10]. It could not be recom-
mended, however, to correlate linearly surviv-
al with age or to predict the recurrence and re-
sponse to therapy of an individual patient based 
on age alone.
Among major risk factors of breast cancer, be-
sides age, are often included: family history of 
breast cancer, menopause in old age, long sup-
plementary hormone therapy, indolent prolitera-
tive breast disease, and carrying genes BRCA1 and 
BRCA2. Histolic grade, Nottingham Prognostic 
Index, lymph node stage, age, oestrogen recep-
tor (ER) and progesterone receptor (PgR) sta-
tus, and tumour size have previously been shown 
to be important prognostic indicators for distant 
recurrence of breast cancer [11,12].
In various types of cancer there have been pro-
posed prognostic indices which are derived by 
multiple regression analysis of number of patients, 
diseases and treatment parameters [13,14]. For 
instance, when used simultaneously in a seven-
variable regression equation, the levels of bicarbo-
nate, alanine transaminase, alkaline phosphatase, 
sodium, potassium, urea and uric acid, together 
with erythrocyte sedimentation rate and patient 
age, appeared signiﬁ cant as prognostic factors for 
survival in small-cell lung cancer [13].
The fundamental problem with multiple regres-
sion analysis is that the parameters (independ-
ent variables) considered simultaneously cannot 
be mutually related, i.e. they should be orthog-
onal [15]. It is difﬁ cult to ﬁ nd a representative 
(and sufﬁ ciently large for statistical reasons) set 
of treatment parameters which would be orthog-
onal. Therefore, prognostic indices derived by 
means of multiple regression analysis, having 
otherwise advantages too (e.g. interpretability 
which can be of value for prognosis and appropriate adjustment of the treat-
ment of breast cancer.
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of the coefﬁ cients), can sometimes be of rather 
limited reliability if there are a lot of interactions 
among the data to be considered.
Artiﬁ cial neural network (ANN) analysis is a new 
method of data analysis, which is to emulate the 
brain’s way of working. Neural nets exhibit the 
way in which arrays of neurons possess function 
in biological learning and memory recognition. 
ANNs differ from classical computer programs 
because they “learn” from a set of examples rath-
er than being programmed to get the right an-
swer. The information is encoded in the strength 
of the network’s “synaptic” connections [16,17]. 
In chemistry and related ﬁ elds of research, inter-
est in neural-network computing has been not-
ed since 1986 [18,19]. ANNs have found appli-
cation in compound classiﬁ cation, modelling 
of structure-activity relationships, identiﬁ cation 
of potential drug targets and the localization of 
structural and functional features of biopolymers 
[20–29]. ANNs are a sophisticated tool for explo-
ration of complex data sets. Because of their abil-
ity to mimic a number of relationships, they are 
used to process clinical data, too. Conﬁ rmation 
of that fact can be found in the literature, includ-
ing ANNs’ usefulness in oncology and studies on 
breast cancer [29–33].
The general idea of principal component analy-
sis (PCA) is to reduce the dimensionality of the 
original multivariable data set by a ﬁ nding line-
ar combination of those variables that explains 
most of the variability within the set of data con-
sidered. By means of PCA, systematic informa-
tion initially dispersed over a large matrix of in-
put variables (often intercorrelated) is extracted 
and condensed in a few abstract variables. Usually 
a few principal components (PCs) are used to de-
termine the abstract variable projection on the 
plane or in three-dimensional space [34]. PCA al-
lows the principal components to be found given 
either the original variables or a correlation or 
covariance matrix. Coefﬁ cients of each principal 
component are determined by computing the ei-
genvalues of the covariance matrix or the corre-
lation matrix. Standard commercially available 
computer programs provide the eigenvalues, the 
component weight and the values of individual 
principal components. Especially convenient are 
plots of component weights for the ﬁ rst two PCs 
for each variable and the scatterplots for the ﬁ rst 
two PCs illustrating distribution of objects [18]. 
Projections of data points ascribed to individual 
objects (patients) and to individual variables re-
ﬂ ect mutual similarities and dissimilarities among 
Variable No. Variable Name
1
Age (in years)
(1) <30
(2) 31–50
(3) 51–60
(4) >60
2
Period of hormonal activity (in years)
(1) <10
(2) 11–20
(3) 21–30
(4) 31–40
(5) >40
3
Number of childbirths
(1) 0
(2) 1
(3) 2
(4) 3
(5) >4
4
Size of tumour
(1) no data available
(2) <40
(3) >40
5
Involvement of auxiliary lymph nodes
(1) no involvement
(2) 1–3
(3) 4–8
(4) >8
6
Emboli from carcinoma cells in the vessels
(1) yes
(2) no
7
Degree of malignancy according to Bloom
(1) I
(2) II
(3) III
8
The type of hormonal adjuvant therapy
(1) no hormonal adjuvant therapy
(2) tamoxifen
9
Familial incidence of cancer
(1) yes
(2) no
10
Professional activity
(1) intellectual
(2) physical
(3) no profession
11
Residence place
(1) Poznań
(2) outside Poznań
Category
Category
(1) recurrence
(2) no recurrence 
Table 1. Variables considered in the analysis by artifi cial neural 
network (ANN). 
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them. That way, the basic part of information on 
the objects and on the variables can be exploited 
by our mind, which naturally visualizes only rela-
tionships in up to three dimensional space.
The work was aimed at application of ANNs as 
convenient and reliable prognostics in breast 
cancer. Our former publications demonstrated 
preliminarily the use of PCA [35] and ANN [36] 
for 228 breast cancer patients after mastectomy. 
In this project the approach has been tested and 
revisited on the material available for 718 breast 
cancer patients after mastectomy that were treat-
ed and observed in the Chemotherapy Unit, 
Oncology Centre of Wielkopolska (Greatpoland 
Cancer Centre) in Poznań, Poland. Mastectomy 
was done in 1992/1994 in the Surgery Unit of 
the same institution. Patient observation was car-
ried on until 2002/2004.
AIM
The purpose of the work is to demonstrate that 
ANN and PCA are convenient and reliable prog-
nostic tools in prediction of recurrence incidenc-
es within a 10-year period after mastectomy in 
the case of breast cancer. By these methods one 
can exploit all the types of information on pa-
tient, disease and treatment, making use in a sin-
gle analysis of variables ranging from sociologi-
cal to genetic ones.
MATERIALS AND METHODS
Patient characteristics
Data on 718 patients with breast cancer were ret-
rospectively collected and analyzed. The variables 
considered in this study are presented in Table 1. A 
total number of 11 variables were subjected to ANN 
and PCA analyses. The ﬁ nal matrix of data subject-
ed to ANN and PCA analyses was 718 patients times 
11 variables. Table 2 presents the data for 6 selected 
patients with and without recurrence of breast can-
cer within a 10-year period after mastectomy.
ANN analysis
Artiﬁ cial neural networks (ANN) were run on 
a personal computer using Statistica Neural 
Networks v. 6 software (StatSoft, Tulsa, OK, USA). 
In the ﬁ rst phase of the analysis, the number of 
hidden neurons was determined experimentally. 
For the choice of the appropriate network mod-
el, the coefﬁ cient value of the correct classiﬁ ca-
tion with respect to validation of the set of data 
was taken into account. No distinct differenc-
es in classiﬁ cation coefﬁ cient were observed for 
networks differing in the number of hidden neu-
rons. The results are presented in Table 3. The 
size of individual sets of data was deﬁ ned on the 
basis of the assumed division of the sample ac-
cording to the scheme as follows: 358:180:180. 
That means that 50% of cases were assigned to 
the learning set, 25% of cases were in the valida-
tion set, and 25% of cases were in the testing set. 
Individual patients were classiﬁ ed randomly to 
each set. The evaluation of the inﬂ uence of the 
decrease of learning set on the predictive prop-
erties was also evaluated (Table 4).
For further investigation, an artiﬁ cial neural net-
work based on a multilayer perceptron consist-
ing of 11 artiﬁ cial neurons in the input layer, 9 
in the hidden layer and 1 neuron in the output 
layer was used. The architecture of the model 
used is depicted in Figure 1. The method of su-
pervised learning with back-propagation strategy 
and conjugate gradient descent method was used. 
Variables for patients analyzed were divided into 
three sets: learning set with 358 patients, validating 
set with 180 patients and testing set with 180 pa-
tients. The learning process was completed when 
the artiﬁ cial neural network was characterized by 
the least RMS error. In the case of the network 
applied, learning was completed in 50 epochs by 
back propagation (BP) method and 2 epochs by 
conjugate gradient descent (CGD) method. Data 
from the learning set were presented in a rand-
omized manner during the learning process.
PCA analysis
Principal component analysis of the 718×11 data 
matrix was performed by means of the Statistica 
v. 6 computer program (StatSoft Inc, Tulsa, OK, 
USA) operated on a personal computer. It was 
found that the two ﬁ rst principal components, 
PC1 and PC2, accounted cumulatively for 37.5% 
of the total variance in the data described with 
11 original variables.
The projection of points assigned to individual pa-
tients (principal component “scores”) in the space 
determined by the ﬁ rst two principal components 
axes, PC1 and PC2, is depicted in Figure 2.
The variables positioned in the space determined 
by the ﬁ rst principal components produced a plot 
of principal component “loadings”. The principal 
components most signiﬁ cant for separation of pa-
tients (“object scores”) in Figure 2 are PC1 and 
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Variable No. Variable name
Variable value for patient
No. 1 No. 2 No. 3 No. 4 No. 5 No. 6
1 Age (in years) 2 3 2 2 3 2
2 Period of hormonal activity (in years) 3 4 3 4 4 4
3 Number of childbirths 3 1 1 3 2 1
4 Size of tumour 3 3 3 2 2 2
5 Involvement of auxiliary lymph nodes 4 3 3 2 1 1
6 Emboli from carcinoma cells in the vessels 2 2 1 2 2 2
7 Degree of malignancy according to Bloom 3 3 3 1 1 1
8 The type of hormonal adjuvant therapy 1 1 1 2 2 1
9 Familial incidences of cancer 2 1 2 2 2 1
10 Professional activity 2 2 1 2 1 1
11 Residence place 1 2 2 1 1 2
Category R R R NR NR NR
Table 2. Variables considered in analysis by artifi cial neural network (ANN) and their values for six example patients.
Recurrence (R); No recurrence (NR).
No. Typ ANN CR* learning set CR validation set CR testing set
1 MLP 11: 11-9-1: 1 0.757 0.767 0.767
2 MLP 11: 11-4-5-1: 1 0.737 0.761 0.761
3 MLP 11: 11-14-14-1: 1 0.737 0.761 0.794
4 MLP 11: 11-9-9-1: 1 0.735 0.761 0.772
5 MLP 11: 11-14-1: 1 0.743 0.756 0.778
6 MLP 11: 11-5-1: 1 0.743 0.750 0.767
7 MLP 11: 11-22-22-1: 1 0.740 0.733 0.778
Table 3. Classifi cation results for six ANN models diff ering in the number of hidden neurons.
* CR – Classifi cation rate.
No. Size of individual sets of data(learning: validation: testing) ANN model type
CR
learning set
CR
validation set
CR
testing set
1
2
3
478: 120: 120
MLP 11: 11-12-1: 1 0.799 0.717 0.625
MLP 11: 11-11-1: 1 0.791 0.725 0.658
MLP 11: 11-13-1: 1 0.795 0.708 0.633
4
5
6
538: 90: 90
MLP 11: 11-13-1: 1 0.818 0.767 0.678
MLP 11: 11-13-1: 1 0.801 0.667 0.689
MLP 11: 11-11-1: 1 0.810 0.722 0.689
7
8
9
538: 150: 30
MLP 11: 11-13-1: 1 0.803 0.700 0.500
MLP 11: 11-11-1: 1 0.812 0.740 0.600
MLP 11: 11-8-1: 1 0.783 0.720 0.533
Table 4. Results for ANN with respect to diff erent size of each set of data.
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PC2. Therefore in Figure 3 the “loadings” of PC1 
and PC2 by individual variables are presented.
RESULTS
Figure 1 presents the architecture of the ANN mod-
el used for predictions of breast cancer recurrence 
within a 10-year period after mastectomy based 
on the input data from training, validating and 
testing data sets, respectively.
In Table 5 classiﬁ cation statistics are collected for 
training, validating and testing sets. Receiver op-
erating characteristic curves (ROC curves) are 
shown in Figure 4.
Using the proposed method it was possible to differ-
entiate patients in the testing group as with or with-
out breast cancer recurrence with prognostic poten-
cy at the level of 75%. The prognostic potency of 
ANN regarding the set of test patients is reasonably 
Figure 1. Architecture of artifi cial neural network used in 
predictions of recurrence of breast cancer within 10 years after 
mastectomy.
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Figure 2. Projection of 718 points denoting patients (described by 
11 variables listed in Table 1) in the space of the fi rst two principal 
components, PC1 and PC2, from principal component analysis 
(PCA) of a 718×11 data matrix.
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good and proves the appropriate choice and shape 
of the network proposed. 142 patients in the test-
ing set of a total number of 180 have been correct-
ly classiﬁ ed, which means that one is able to predict 
the breast cancer recurrence utilizing the variables 
used with high probability reaching 79%.
Parallel with ANN statistics, also ANN sensitiv-
ity analysis for input variables was performed 
(Table 6). Sensitivity analysis provides insight 
into the usefulness of individual variables. With 
this kind of analysis it is possible to judge what 
parameters are the most signiﬁ cant (with sensi-
tivity value close to 1) and the least signiﬁ cant 
(with sensitivity value close to 10) during gener-
ation of the satisfactory ANN. According to sen-
sitivity analysis the degree of malignancy accord-
ing to Bloom is the most signiﬁ cant parameter 
to distinguish patients with and without breast 
cancer recurrence. Highly signiﬁ cant are also 
the size of tumour, period of hormonal activity 
and age. Less signiﬁ cant appear to be number 
of childbirths, familiar accidences of cancer and 
the type of hormonal adjuvant therapy.
Principal component analysis also extracts sys-
tematic information on the variables consid-
ered. The most interesting are variables directly 
connected with the negative prognosis of recur-
rence 10 years after the mastectomy. Almost all 
variables considered are directly associated with 
recurrence process in this kind of analysis, ex-
cept emboli from carcinoma cells in the vessels 
and to a lesser extent the type of hormonal ad-
juvant therapy, period of hormonal activity and 
age. These variables are located in the lower side 
of Figure 3.
Lower values of PC2 for patients (closed circles 
in Figure 2) suggest no recurrence among these 
patients. On the basis of PCA analysis it could be 
assumed that the involvement of auxiliary lymph 
nodes, size of tumour and degree of malignan-
cy according to Bloom generate in an especial-
ly signiﬁ cant manner the recurrence of breast 
cancer of the patients 10 years after mastectomy 
(Figure 3). This is conﬁ rmed also by the results 
obtained in sensitivity analysis of the ANN meth-
od. According to that analysis, size of tumour and 
Learning set Validation set Testing set
No recurrence Recurrence No recurrence Recurrence No recurrence Recurrence
Total 153 205 67 113 66 114
Correct 108 157 58 82 52 90
Wrong 45 48 9 31 14 24
Table 5. Classifi cation statistics for ANN used.
Variable No. Variable name Rank Error
1 Age (in years) 4 0.4313
2 Period of hormonal activity (in years) 3 0.4322
3 Number of childbirths 11 0.4267
4 Size of tumour 2 0.4467
5 Involvement of auxiliary lymph nodes 6 0.4299
6 Emboli from carcinoma cells in the vessels 7 0.4287
7 Degree of malignancy according to Bloom 1 0.4484
8 The type of hormonal adjuvant therapy 9 0.4274
9 Familial incidences of cancer 10 0.4268
10 Professional activity 5 0.4310
11 Residence place 8 0.4280
Table 6. Sensitivity analysis results for the variables considered in artifi cial neural network (ANN) analysis. 
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degree of malignancy according to Bloom consid-
ering the possibility of breast cancer recurrence 
of patients 10 years after mastectomy should be 
taken into special account. However, the involve-
ment of auxiliary lymph nodes was treated in this 
case as less signiﬁ cant.
DISCUSSION
The prognostic factors identiﬁ ed by both types of 
analysis (ANN and PCA) as Bloom grade and tu-
mour size are well known in breast cancer predic-
tion [38–44]. Another analyzed histological grade 
– involvement of lymph nodes – is usually identi-
ﬁ ed as a signiﬁ cant prognostic factor in different 
types of multivariate and univariate analysis and 
it is always highly correlated with the other two 
histological components [39]. The undertaken 
ANN analysis did not recognize its strong prog-
nostic power (rank 6 of sensitivity). One reason 
could be the character of the database, where al-
most half of the group was negative lymph nodes. 
Regarding the representativeness of the analyzed 
matrix, the advantageous utilization of just two 
of them (Bloom grade and tumour size) can be 
concluded.
Among the most signiﬁ cant predictive variables, 
menopausal status (ANN sensitivity rank 3) and 
age (ANN sensitivity rank 4) were identiﬁ ed, which 
are often recognized as sensitive factors [40]. The 
PCA analysis revealed that these two factors repre-
sent a different direction of variability (PCA axis 1) 
than Bloom grade and tumour size (PCA axis 2). 
Combining variables representing both revealed di-
rections of variability would beneﬁ t in sensitiveness 
of the proposed combination of risk factors.
CONCLUSIONS
The large potential of the neural network has 
been proved based on clinical studies in breast 
cancer and several comparisons with other ana-
lytical techniques have been undertaken [32,45–
47]. The presented study shows the valuable 
application of ANN and PCA to breast cancer 
recurrence prediction due to the valuable orig-
inal data set analysis based on uniform long-
term records. The undertaken analysis is most-
ly explanatory in character, which may help to 
identify a combination of factors providing an 
effective treatment and a good prognosis, the 
more so that ANN and PCA analyses allow for 
testing a practically unlimited number of either 
mutually related or apparently unrelated fac-
tors and cases.
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